Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Undergraduate Student Research Awards (USRA)

University of Alberta

$6,000.00

Caveolin-1 Dependent Respiratory Syncytial Virus Infection

FY 2023-24

Summary
Emily will be studying Respiratory Syncytial Virus (RSV), which is the leading cause of infant hospitalizations worldwide. There is no vaccine and no therapeutics. Our lab study the entry phase of RSV including new entry receptors for RSV that we discovered in 2020 (Griffiths et al. and Marchant. Nature, 2020). We study RSV entry to identify new therapeutic targets so that new treatments for RSV infections can be developed. Emily will be studying the human gene Caveolin-1 (CAV1) and how it affects RSV receptor binding, entry, replication, and budding from the cell. CAV1 is known to bind to cholesterol and concentrate it in lipid rafts and caveolae. We have found that CAV-1 is necessary for entry. Our Preliminary data suggest that RSV needs CAV1 in its envelope to for entry and infection. Our working model is that the cholesterol in the membrane concentrated by CAV1 stabilizes the RSV glycoproteins inserted in the virus membrane and supports the extreme curvature of the virus particle membrane during the entry fusion reaction of the viral and host membranes. If RSV doesn't have CAV1 there is less cholesterol in the virus particle membrane and so it is less stable during fusion. This makes the virus less infectious.
Program
Undergraduate Student Research Awards (USRA)
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486943
Name
Kimani Emily
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Caveolin-1 Dependent Respiratory Syncytial Virus Infection
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Alberta
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Fusion; Gene; Hospitalizations; Human; Infant; Infectious; Membrane; Virus
Abstract
Emily will be studying Respiratory Syncytial Virus (RSV), which is the leading cause of infant hospitalizations worldwide. There is no vaccine and no therapeutics. Our lab study the entry phase of RSV including new entry receptors for RSV that we discovered in 2020 (Griffiths et al. and Marchant. Nature, 2020). We study RSV entry to identify new therapeutic targets so that new treatments for RSV infections can be developed. Emily will be studying the human gene Caveolin-1 (CAV1) and how it affects RSV receptor binding, entry, replication, and budding from the cell. CAV1 is known to bind to cholesterol and concentrate it in lipid rafts and caveolae. We have found that CAV-1 is necessary for entry. Our Preliminary data suggest that RSV needs CAV1 in its envelope to for entry and infection. Our working model is that the cholesterol in the membrane concentrated by CAV1 stabilizes the RSV glycoproteins inserted in the virus membrane and supports the extreme curvature of the virus particle membrane during the entry fusion reaction of the viral and host membranes. If RSV doesn't have CAV1 there is less cholesterol in the virus particle membrane and so it is less stable during fusion. This makes the virus less infectious.
Competitiondate
202305
Approvedterm2
0 yr 4 mths
Pinamesdelim
Kimani, Emily
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~
University of Alberta - $6,000 Grant (2023-24) | Canada Spends